Ontology type: schema:ScholarlyArticle
2018-04
AUTHORSMohammed F. K. Ibrahim, John Hilton, Sasha Mazzarello, Dean Fergusson, Brian Hutton, Andrew Robinson, Nadia Califaretti, Tina Hsu, Stan Gertler, Mihaela Mates, Carol Stober, Lisa Vandermeer, Ranjeeta Mallick, Mark Clemons
ABSTRACTINTRODUCTION: The most effective duration of filgrastim as primary febrile neutropenia (FN) prophylaxis in early breast cancer (EBC) patients is unknown. Despite significant differences in cost and toxicity, no prospective trial has been performed to optimize practice. We assessed the feasibility of using a novel pragmatic trial model to compare the most commonly used schedules of filgrastim. METHODS: Early breast cancer patients receiving chemotherapy were randomized to 5, 7, or 10 days of filgrastim as primary FN prophylaxis. The trial methodology integrated broad eligibility criteria, simply defined endpoints, an integrated consent model incorporating oral consent, and web-based randomization in the clinic. Feasibility was reflected through a combination of primary endpoints including patient and physician engagement (if > 50% of appropriate patients approached agree to participate, and if > 50% of physicians approached patients for the study). Secondary endpoints included the first occurrence rates of FN, treatment-related hospital admission, or chemotherapy dose reductions/delays/discontinuation. RESULTS: From May 2015 to August 2016, 142/149 (95.3%) patients approached agreed to participate and were randomized. Seventeen of 24 (70.8%) medical oncologists approached and randomized patients. The 142 patients received a total of 495 cycles of chemotherapy. Aggregate incidences of a first event by patient were FN (8/142, 5.6%), treatment-related hospitalization (6/142, 4.2%), chemotherapy discontinuation (7/142, 4.9%), chemotherapy delays (5/142, 3.5%), and chemotherapy dose reduction (18/142, 12.7%). Overall, 31.7% (45/142) of patients and 9.0% (45/495) of chemotherapy cycles were associated with one of these first events. CONCLUSION: This study met its feasibility endpoints. This novel pragmatic trial approach offers a means of comparing standard of care treatments in a practical and cost-effective manner. The trial will now be expanded to compare rates of FN between the three filgrastim schedules. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02428114. More... »
PAGES371-379
http://scigraph.springernature.com/pub.10.1007/s10549-017-4604-y
DOIhttp://dx.doi.org/10.1007/s10549-017-4604-y
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1099700092
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/29214415
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Combined Chemotherapy Protocols",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Breast Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Chemotherapy-Induced Febrile Neutropenia",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cost-Benefit Analysis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Administration Schedule",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Feasibility Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Filgrastim",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Hematologic Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Incidence",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neoplasm Staging",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Ontario",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Practice Guidelines as Topic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Standard of Care",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Time Factors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Young Adult",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "University of Ottawa",
"id": "https://www.grid.ac/institutes/grid.28046.38",
"name": [
"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Canada"
],
"type": "Organization"
},
"familyName": "Ibrahim",
"givenName": "Mohammed F. K.",
"id": "sg:person.012754470322.02",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012754470322.02"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Ottawa Hospital",
"id": "https://www.grid.ac/institutes/grid.412687.e",
"name": [
"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Canada",
"Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada"
],
"type": "Organization"
},
"familyName": "Hilton",
"givenName": "John",
"id": "sg:person.01011642231.93",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011642231.93"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Ottawa Hospital",
"id": "https://www.grid.ac/institutes/grid.412687.e",
"name": [
"Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada"
],
"type": "Organization"
},
"familyName": "Mazzarello",
"givenName": "Sasha",
"id": "sg:person.0737376756.24",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737376756.24"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Ottawa Hospital",
"id": "https://www.grid.ac/institutes/grid.412687.e",
"name": [
"Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada",
"Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Canada"
],
"type": "Organization"
},
"familyName": "Fergusson",
"givenName": "Dean",
"id": "sg:person.01152765352.19",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152765352.19"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Ottawa Hospital",
"id": "https://www.grid.ac/institutes/grid.412687.e",
"name": [
"Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada",
"Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Canada"
],
"type": "Organization"
},
"familyName": "Hutton",
"givenName": "Brian",
"id": "sg:person.01235465321.38",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235465321.38"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Cancer Care South East",
"id": "https://www.grid.ac/institutes/grid.477028.e",
"name": [
"Cancer Centre of Southeastern Ontario, Kingston, Canada"
],
"type": "Organization"
},
"familyName": "Robinson",
"givenName": "Andrew",
"id": "sg:person.014571461331.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014571461331.20"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"Grand River Regional Cancer Centre, Kitchener, Canada"
],
"type": "Organization"
},
"familyName": "Califaretti",
"givenName": "Nadia",
"id": "sg:person.01022250610.11",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022250610.11"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Ottawa",
"id": "https://www.grid.ac/institutes/grid.28046.38",
"name": [
"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Canada"
],
"type": "Organization"
},
"familyName": "Hsu",
"givenName": "Tina",
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Ottawa",
"id": "https://www.grid.ac/institutes/grid.28046.38",
"name": [
"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Canada"
],
"type": "Organization"
},
"familyName": "Gertler",
"givenName": "Stan",
"id": "sg:person.01230721252.04",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230721252.04"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Cancer Care South East",
"id": "https://www.grid.ac/institutes/grid.477028.e",
"name": [
"Cancer Centre of Southeastern Ontario, Kingston, Canada"
],
"type": "Organization"
},
"familyName": "Mates",
"givenName": "Mihaela",
"id": "sg:person.01201550771.63",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201550771.63"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Ottawa Hospital",
"id": "https://www.grid.ac/institutes/grid.412687.e",
"name": [
"Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada"
],
"type": "Organization"
},
"familyName": "Stober",
"givenName": "Carol",
"id": "sg:person.012546702415.53",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012546702415.53"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Ottawa Hospital",
"id": "https://www.grid.ac/institutes/grid.412687.e",
"name": [
"Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada"
],
"type": "Organization"
},
"familyName": "Vandermeer",
"givenName": "Lisa",
"id": "sg:person.0761055556.65",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761055556.65"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Ottawa Hospital",
"id": "https://www.grid.ac/institutes/grid.412687.e",
"name": [
"Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada"
],
"type": "Organization"
},
"familyName": "Mallick",
"givenName": "Ranjeeta",
"id": "sg:person.0657754474.04",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657754474.04"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Ottawa Hospital",
"id": "https://www.grid.ac/institutes/grid.412687.e",
"name": [
"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Canada",
"Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada"
],
"type": "Organization"
},
"familyName": "Clemons",
"givenName": "Mark",
"id": "sg:person.01216107435.90",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216107435.90"
],
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1016/j.ejca.2010.10.001",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1006780383"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00520-011-1375-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017473885",
"https://doi.org/10.1007/s00520-011-1375-6"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2015.62.3488",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1021783900"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/annonc/mdm438",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1024333619"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jop.2016.013474",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1029512117"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2009.23.0508",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1032930162"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.ejca.2010.10.013",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1034049872"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/annonc/mdq196",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1034733668"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/annonc/mdq196",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1034733668"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/14651858.cd007913.pub2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1036547737"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.3747/co.v18i3.751",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037734300"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1001/jama.2014.4164",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037858442"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.3747/co.20.1306",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1038319021"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.3747/co.v17i2.498",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1039793562"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1136/bmj.i5239",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1043964837"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/1472-6963-14-189",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050821717",
"https://doi.org/10.1186/1472-6963-14-189"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmhle1312508",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051027676"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/annonc/mdq195",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052859374"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/annonc/mdq195",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052859374"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.6004/jnccn.2013.0148",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1078801616"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.6004/jnccn.2013.0148",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1078801616"
],
"type": "CreativeWork"
}
],
"datePublished": "2018-04",
"datePublishedReg": "2018-04-01",
"description": "INTRODUCTION: The most effective duration of filgrastim as primary febrile neutropenia (FN) prophylaxis in early breast cancer (EBC) patients is unknown. Despite significant differences in cost and toxicity, no prospective trial has been performed to optimize practice. We assessed the feasibility of using a novel pragmatic trial model to compare the most commonly used schedules of filgrastim.\nMETHODS: Early breast cancer patients receiving chemotherapy were randomized to 5, 7, or 10\u00a0days of filgrastim as primary FN prophylaxis. The trial methodology integrated broad eligibility criteria, simply defined endpoints, an integrated consent model incorporating oral consent, and web-based randomization in the clinic. Feasibility was reflected through a combination of primary endpoints including patient and physician engagement (if\u00a0>\u00a050% of appropriate patients approached agree to participate, and if\u00a0>\u00a050% of physicians approached patients for the study). Secondary endpoints included the first occurrence rates of FN, treatment-related hospital admission, or chemotherapy dose reductions/delays/discontinuation.\nRESULTS: From May 2015 to August 2016, 142/149 (95.3%) patients approached agreed to participate and were randomized. Seventeen of 24 (70.8%) medical oncologists approached and randomized patients. The 142 patients received a total of 495 cycles of chemotherapy. Aggregate incidences of a first event by patient were FN (8/142, 5.6%), treatment-related hospitalization (6/142, 4.2%), chemotherapy discontinuation (7/142, 4.9%), chemotherapy delays (5/142, 3.5%), and chemotherapy dose reduction (18/142, 12.7%). Overall, 31.7% (45/142) of patients and 9.0% (45/495) of chemotherapy cycles were associated with one of these first events.\nCONCLUSION: This study met its feasibility endpoints. This novel pragmatic trial approach offers a means of comparing standard of care treatments in a practical and cost-effective manner. The trial will now be expanded to compare rates of FN between the three filgrastim schedules.\nTRIAL REGISTRATION: ClinicalTrials.gov: NCT02428114.",
"genre": "research_article",
"id": "sg:pub.10.1007/s10549-017-4604-y",
"inLanguage": [
"en"
],
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1092777",
"issn": [
"0167-6806",
"1573-7217"
],
"name": "Breast Cancer Research and Treatment",
"type": "Periodical"
},
{
"issueNumber": "2",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "168"
}
],
"name": "A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer",
"pagination": "371-379",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"a7421fa98a3644b682831eb311feccbb825ac98fcf837ace2d26a01652fbf77a"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"29214415"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"8111104"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s10549-017-4604-y"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1099700092"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s10549-017-4604-y",
"https://app.dimensions.ai/details/publication/pub.1099700092"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-11T12:25",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000362_0000000362/records_87106_00000001.jsonl",
"type": "ScholarlyArticle",
"url": "https://link.springer.com/10.1007%2Fs10549-017-4604-y"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10549-017-4604-y'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10549-017-4604-y'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10549-017-4604-y'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10549-017-4604-y'
This table displays all metadata directly associated to this object as RDF triples.
313 TRIPLES
21 PREDICATES
69 URIs
43 LITERALS
31 BLANK NODES